Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New smart pump system tested for better diabetes control in real life

NCT ID NCT07048795

Disease control Sponsor: mylife Diabetes Care AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study looks at how a new insulin pump system (mylife CamAPS FX with Dexcom G6 sensor) helps people with type 1 diabetes control their blood sugar and improve quality of life. About 125 adults and children in France will use the system for one year while doctors track their progress. The goal is to see if the system makes daily diabetes management easier and safer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will be recruited from 22 French participating centers, which are defined as insulin pump initiation hospital centers according to the definition of the Francophone Diabetic Society.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with type 1 diabetes who have been using a Dexcom or Abbott Libre glucose sensor (any model) for at least 14 days prior to the date of installation of the mylife YpsoPump, with at least 70% coverage, under the same sensor. * Patient for whom the diabetes specialist decides to initiate the mylife CamAPS FX hybrid closed loop. * Patient who received the information sheets and gave their consent to participate in the study and to the processing of their personal data. * Adult patient who signed an informed consent form to participate in the study or minor patient whose parents signed an informed consent form for their child's participation in the study. * Adult patient, minor patient old enough to complete the questionnaires or parent of a minor patient able to read and understand French. * Adult patient / minor patient capable to complete the questionnaires or parent of a minor patient who agrees to complete the online self-questionnaires. Exclusion Criteria: * Patient who used a hybrid closed-loop system, a fully closed-loop system, or a do-it-yourself loop system, regardless of the brand or model, within the past 6 months. * Patients participating or having participated in a clinical trial in the previous month that prevents them from participating in other studies. * Patient or parent unable to give consent. * Protected Patient (subject to a legal protection measure: guardianship, curatorship or legal safeguard). * Patient with a contraindication to the prescription of the mylife CamAPS FX hybrid closed-loop ( according to the Instructions For Use, IFU). * Patient with an unresolved skin condition in the area of sensor placement and/or in the tubing placement area (e.g. psoriasis, dermatitis herpetiformis, rash, staphylococcal infection). * Patient with unstable diabetic retinopathy requiring laser treatment. * Patient with a concomitant condition or treatment that alters glucose metabolism and that, in the investigator's judgment, is likely to have a significant impact on glycemic control; * Patient whose follow-up cannot be carried out by the centre (relocation planned within 12 months of inclusion).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes type 1

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    22 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • CH Bretagne Atlantique

    RECRUITING

    Vannes, 56017, France

  • CH Périgueux

    RECRUITING

    Périgueux, 24000, France

  • CH Victor Dupouy

    RECRUITING

    Argenteuil, 95107, France

  • CHRU Nancy-Hôpitaux de Brabois Adultes

    RECRUITING

    Vandœuvre-lès-Nancy, 54511, France

  • CHU Amiens

    RECRUITING

    Amiens, 80054, France

  • CHU Brest - Hôpital La Cavale Blanche

    RECRUITING

    Brest, 29609, France

  • CHU Grenoble Alpes

    RECRUITING

    Grenoble, 38042, France

  • CHU Poitiers

    RECRUITING

    Poitiers, 86021, France

  • CHU Toulouse

    RECRUITING

    Toulouse, 31059, France

  • CHU de Bordeaux

    RECRUITING

    Bordeaux, 33000, France

  • Clinique Pasteur

    RECRUITING

    Toulouse, 31300, France

  • Groupe Hospitalier de la Rochelle Ré Aunis

    RECRUITING

    La Rochelle, 17019, France

  • Groupe hospitalier Bichat Claude Bernard

    RECRUITING

    Paris, 75018, France

  • Hospices Civils de Lyon DIAB-Ecare

    RECRUITING

    Lyon, 69008, France

  • Hôpital Bois Guillaume

    RECRUITING

    Bois-Guillaume, 76230, France

  • Hôpital Europeen Georges Pompidou

    RECRUITING

    Paris, 75015, France

  • Hôpital Européen

    RECRUITING

    Marseille, 13003, France

  • Hôpital Femme Mère Enfant Lyon

    RECRUITING

    Bron, 69677, France

  • Hôpital NOVO, Site Pontoise

    RECRUITING

    Pontoise, 95300, France

  • Hôpital Robert Schuman-UNEOS

    RECRUITING

    Vantoux, 57070, France

  • Hôpital Universitaire Necker Enfants Malades

    RECRUITING

    Paris, 75015, France

  • Hôtel Dieu-Pédiatrie

    RECRUITING

    Angers, 49933, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.